P&G Kisses Pharma Business Goodbye In $3.1 Billion Deal With Warner Chilcott
This article was originally published in The Pink Sheet Daily
Ireland-based Warner Chilcott has a "double tax haven," making the P&G deal one with fairly low financial risks, Wall Street analysts say.
You may also be interested in...
A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.